Compare Harley-Davidson Inc (HOG) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Harley-Davidson Inc trades at $26.86 (market cap $2.78B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 21.1× Harley-Davidson Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| HOG | TAK | |
|---|---|---|
Market Cap | $2.78B | $58.74B |
Volume | 2,966,389 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $19.05 |
52-Week Low | $17.19 | $13.23 |
Typical Hold Time | 92 Days | 1 Days |
Enterprise Value | $3.20B | $86.65B |
Dividend Yield | 2.8% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.90, down 0.19% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings beat ($0.75 vs $0.645 expected) but missed Q1 expectations. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 14.86 and P/S of 0.72. Recent news highlights tariff exposure and a data breach investigation.
The stock offers value with reasonable multiples but faces revenue headwinds and operational challenges. Analyst consensus is cautious with 61% hold ratings and $28.50 price target suggesting limited upside. Key risks include declining motorcycle demand, tariff sensitivity, and competitive pressures in the evolving auto industry.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
